Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson’s disease
Highlights • A novel three-point intrastriatal rotenone rat model of Parkinson’s disease was used. • Chronic treatment with valproic acid abolished forelimb motor dysfunction in this model. • Valproic acid also blocked the loss of dopamine neurons in the substantia nigra. • First evidence of neuropr...
Gespeichert in:
| Veröffentlicht in: | Neuroscience 2014-05, Vol.267, p.114-121 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 121 |
|---|---|
| container_issue | |
| container_start_page | 114 |
| container_title | Neuroscience |
| container_volume | 267 |
| creator | Carriere, C.H Kang, N.H Niles, L.P |
| description | Highlights • A novel three-point intrastriatal rotenone rat model of Parkinson’s disease was used. • Chronic treatment with valproic acid abolished forelimb motor dysfunction in this model. • Valproic acid also blocked the loss of dopamine neurons in the substantia nigra. • First evidence of neuroprotection by valproic acid in an intracranial rotenone model. |
| doi_str_mv | 10.1016/j.neuroscience.2014.02.028 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1518246948</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0306452214001407</els_id><sourcerecordid>1518246948</sourcerecordid><originalsourceid>FETCH-LOGICAL-c380t-e2866beb4d60f30232b525df7c106ff4f12c3cc6cf7dee9c3a17e4e3fc24c6133</originalsourceid><addsrcrecordid>eNqNktuKFDEQhoO4uOPqK0gQBG96zKkP64WwrEdYVFDvhJCurkBme5I16V6YO1_D19snsZoZdfFqQ5FA-Or0VzH2VIq1FLJ5sVlHnHMqEDACrpWQZi0UWXePrWTX6qqtjbnPVkKLpjK1UsfsYSkbQac2-gE7VqaRulVqxb5_XEJd5TQhTCFF3u_4tRvpIwB3EAYeIneR7im7MuXgJjfyBY8pIt-mAUeePP_s8mWIJcWbn78KH0JBV_ARO_JuLPj48J6wb2_ffD1_X118evfh_OyiAt2JqULVNU2PvRka4bVQWvW1qgffghSN98ZLBRqgAd8OiKegnWzRoPagDFAj-oQ938elsn_MWCa7DQVwHF3ENBcra9lRy6emI_TlHgUSsGT09iqHrcs7K4Vd1LUbe1tdu6hrhSJbnJ8c8sz9Foe_rn_kJODZAXAF3OizixDKP64zTU1DIe71nkNS5Tpgtod0Q8g0BzukcLd6Xv0XBsYQA2W-xB2WTZpzJN2ttIUc7JdlH5Z1kEZQFNHq32CwtsU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1518246948</pqid></control><display><type>article</type><title>Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson’s disease</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Carriere, C.H ; Kang, N.H ; Niles, L.P</creator><creatorcontrib>Carriere, C.H ; Kang, N.H ; Niles, L.P</creatorcontrib><description>Highlights • A novel three-point intrastriatal rotenone rat model of Parkinson’s disease was used. • Chronic treatment with valproic acid abolished forelimb motor dysfunction in this model. • Valproic acid also blocked the loss of dopamine neurons in the substantia nigra. • First evidence of neuroprotection by valproic acid in an intracranial rotenone model.</description><identifier>ISSN: 0306-4522</identifier><identifier>EISSN: 1873-7544</identifier><identifier>DOI: 10.1016/j.neuroscience.2014.02.028</identifier><identifier>PMID: 24613722</identifier><identifier>CODEN: NRSCDN</identifier><language>eng</language><publisher>Amsterdam: Elsevier Ltd</publisher><subject>Analysis of Variance ; Animals ; Anticonvulsants. Antiepileptics. Antiparkinson agents ; Biological and medical sciences ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Disease Models, Animal ; Dopaminergic Neurons - pathology ; Functional Laterality ; Insecticides - toxicity ; intrastriatal ; Male ; Medical sciences ; Neurology ; Neuropharmacology ; neuroprotection ; Neuroprotective Agents - blood ; Neuroprotective Agents - therapeutic use ; Parkinson Disease - blood ; Parkinson Disease - complications ; Parkinson Disease - drug therapy ; Parkinson Disease - etiology ; Parkinson’s disease ; Pharmacology. Drug treatments ; Postural Balance - drug effects ; Rats ; Rats, Sprague-Dawley ; rotenone ; Rotenone - toxicity ; Sensation Disorders - drug therapy ; Substantia Nigra - pathology ; Time Factors ; Tyrosine 3-Monooxygenase - metabolism ; valproic acid ; Valproic Acid - blood ; Valproic Acid - therapeutic use</subject><ispartof>Neuroscience, 2014-05, Vol.267, p.114-121</ispartof><rights>IBRO</rights><rights>2014 IBRO</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2014 IBRO. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c380t-e2866beb4d60f30232b525df7c106ff4f12c3cc6cf7dee9c3a17e4e3fc24c6133</citedby><cites>FETCH-LOGICAL-c380t-e2866beb4d60f30232b525df7c106ff4f12c3cc6cf7dee9c3a17e4e3fc24c6133</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0306452214001407$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28465030$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24613722$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carriere, C.H</creatorcontrib><creatorcontrib>Kang, N.H</creatorcontrib><creatorcontrib>Niles, L.P</creatorcontrib><title>Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson’s disease</title><title>Neuroscience</title><addtitle>Neuroscience</addtitle><description>Highlights • A novel three-point intrastriatal rotenone rat model of Parkinson’s disease was used. • Chronic treatment with valproic acid abolished forelimb motor dysfunction in this model. • Valproic acid also blocked the loss of dopamine neurons in the substantia nigra. • First evidence of neuroprotection by valproic acid in an intracranial rotenone model.</description><subject>Analysis of Variance</subject><subject>Animals</subject><subject>Anticonvulsants. Antiepileptics. Antiparkinson agents</subject><subject>Biological and medical sciences</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Disease Models, Animal</subject><subject>Dopaminergic Neurons - pathology</subject><subject>Functional Laterality</subject><subject>Insecticides - toxicity</subject><subject>intrastriatal</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neurology</subject><subject>Neuropharmacology</subject><subject>neuroprotection</subject><subject>Neuroprotective Agents - blood</subject><subject>Neuroprotective Agents - therapeutic use</subject><subject>Parkinson Disease - blood</subject><subject>Parkinson Disease - complications</subject><subject>Parkinson Disease - drug therapy</subject><subject>Parkinson Disease - etiology</subject><subject>Parkinson’s disease</subject><subject>Pharmacology. Drug treatments</subject><subject>Postural Balance - drug effects</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>rotenone</subject><subject>Rotenone - toxicity</subject><subject>Sensation Disorders - drug therapy</subject><subject>Substantia Nigra - pathology</subject><subject>Time Factors</subject><subject>Tyrosine 3-Monooxygenase - metabolism</subject><subject>valproic acid</subject><subject>Valproic Acid - blood</subject><subject>Valproic Acid - therapeutic use</subject><issn>0306-4522</issn><issn>1873-7544</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNktuKFDEQhoO4uOPqK0gQBG96zKkP64WwrEdYVFDvhJCurkBme5I16V6YO1_D19snsZoZdfFqQ5FA-Or0VzH2VIq1FLJ5sVlHnHMqEDACrpWQZi0UWXePrWTX6qqtjbnPVkKLpjK1UsfsYSkbQac2-gE7VqaRulVqxb5_XEJd5TQhTCFF3u_4tRvpIwB3EAYeIneR7im7MuXgJjfyBY8pIt-mAUeePP_s8mWIJcWbn78KH0JBV_ARO_JuLPj48J6wb2_ffD1_X118evfh_OyiAt2JqULVNU2PvRka4bVQWvW1qgffghSN98ZLBRqgAd8OiKegnWzRoPagDFAj-oQ938elsn_MWCa7DQVwHF3ENBcra9lRy6emI_TlHgUSsGT09iqHrcs7K4Vd1LUbe1tdu6hrhSJbnJ8c8sz9Foe_rn_kJODZAXAF3OizixDKP64zTU1DIe71nkNS5Tpgtod0Q8g0BzukcLd6Xv0XBsYQA2W-xB2WTZpzJN2ttIUc7JdlH5Z1kEZQFNHq32CwtsU</recordid><startdate>20140516</startdate><enddate>20140516</enddate><creator>Carriere, C.H</creator><creator>Kang, N.H</creator><creator>Niles, L.P</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140516</creationdate><title>Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson’s disease</title><author>Carriere, C.H ; Kang, N.H ; Niles, L.P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c380t-e2866beb4d60f30232b525df7c106ff4f12c3cc6cf7dee9c3a17e4e3fc24c6133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Analysis of Variance</topic><topic>Animals</topic><topic>Anticonvulsants. Antiepileptics. Antiparkinson agents</topic><topic>Biological and medical sciences</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Disease Models, Animal</topic><topic>Dopaminergic Neurons - pathology</topic><topic>Functional Laterality</topic><topic>Insecticides - toxicity</topic><topic>intrastriatal</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neurology</topic><topic>Neuropharmacology</topic><topic>neuroprotection</topic><topic>Neuroprotective Agents - blood</topic><topic>Neuroprotective Agents - therapeutic use</topic><topic>Parkinson Disease - blood</topic><topic>Parkinson Disease - complications</topic><topic>Parkinson Disease - drug therapy</topic><topic>Parkinson Disease - etiology</topic><topic>Parkinson’s disease</topic><topic>Pharmacology. Drug treatments</topic><topic>Postural Balance - drug effects</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>rotenone</topic><topic>Rotenone - toxicity</topic><topic>Sensation Disorders - drug therapy</topic><topic>Substantia Nigra - pathology</topic><topic>Time Factors</topic><topic>Tyrosine 3-Monooxygenase - metabolism</topic><topic>valproic acid</topic><topic>Valproic Acid - blood</topic><topic>Valproic Acid - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carriere, C.H</creatorcontrib><creatorcontrib>Kang, N.H</creatorcontrib><creatorcontrib>Niles, L.P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carriere, C.H</au><au>Kang, N.H</au><au>Niles, L.P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson’s disease</atitle><jtitle>Neuroscience</jtitle><addtitle>Neuroscience</addtitle><date>2014-05-16</date><risdate>2014</risdate><volume>267</volume><spage>114</spage><epage>121</epage><pages>114-121</pages><issn>0306-4522</issn><eissn>1873-7544</eissn><coden>NRSCDN</coden><abstract>Highlights • A novel three-point intrastriatal rotenone rat model of Parkinson’s disease was used. • Chronic treatment with valproic acid abolished forelimb motor dysfunction in this model. • Valproic acid also blocked the loss of dopamine neurons in the substantia nigra. • First evidence of neuroprotection by valproic acid in an intracranial rotenone model.</abstract><cop>Amsterdam</cop><pub>Elsevier Ltd</pub><pmid>24613722</pmid><doi>10.1016/j.neuroscience.2014.02.028</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0306-4522 |
| ispartof | Neuroscience, 2014-05, Vol.267, p.114-121 |
| issn | 0306-4522 1873-7544 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1518246948 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Analysis of Variance Animals Anticonvulsants. Antiepileptics. Antiparkinson agents Biological and medical sciences Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Disease Models, Animal Dopaminergic Neurons - pathology Functional Laterality Insecticides - toxicity intrastriatal Male Medical sciences Neurology Neuropharmacology neuroprotection Neuroprotective Agents - blood Neuroprotective Agents - therapeutic use Parkinson Disease - blood Parkinson Disease - complications Parkinson Disease - drug therapy Parkinson Disease - etiology Parkinson’s disease Pharmacology. Drug treatments Postural Balance - drug effects Rats Rats, Sprague-Dawley rotenone Rotenone - toxicity Sensation Disorders - drug therapy Substantia Nigra - pathology Time Factors Tyrosine 3-Monooxygenase - metabolism valproic acid Valproic Acid - blood Valproic Acid - therapeutic use |
| title | Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson’s disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T16%3A38%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neuroprotection%20by%20valproic%20acid%20in%20an%20intrastriatal%20rotenone%20model%20of%20Parkinson%E2%80%99s%20disease&rft.jtitle=Neuroscience&rft.au=Carriere,%20C.H&rft.date=2014-05-16&rft.volume=267&rft.spage=114&rft.epage=121&rft.pages=114-121&rft.issn=0306-4522&rft.eissn=1873-7544&rft.coden=NRSCDN&rft_id=info:doi/10.1016/j.neuroscience.2014.02.028&rft_dat=%3Cproquest_cross%3E1518246948%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1518246948&rft_id=info:pmid/24613722&rft_els_id=S0306452214001407&rfr_iscdi=true |